Nanobiotix, Janssen Pharmaceutica Reach Global Licensing and Commercialization Deal

Published on: 

Agreement to focus on the treatment of patients with advanced head and neck cancer.

Nanobiotix, a late-clinical stage biotechnology company, has reached a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the potential of NBTXR3 across solid tumor indications. The treatment is currently being evaluated in patients with advanced head and neck cancer.


As per the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3. Despite having an exclusive license, the deal will not be attributed to territories previously given to Nanobiotix partner LianBio.

“We expect this agreement, and the collaboration it enables, to further drive the expansion of NBTXR3 development and accelerate the realization of its promise for patients in need,” said Bart van Rhijn, chief financial officer, Nanobiotix. “We look forward to maximizing the value of NBTXR3 for our global stakeholders.”

Reference: NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3. Nanobiotix. July 10, 2023. Accessed July 11, 2023.